Carlos Almonacid

Dr. Carlos Almonacid

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
LLLuis Pérez Pérez de Llano
Luis Pérez Pérez de Llano
MMMarc Miravitlles
Marc Miravitlles
RGRafael Golpe
Rafael Golpe
FAFrancisco Javier Alvarez-gutierrez
Francisco Javier Alvarez-gutierrez
CCCarolina Cisneros
Carolina Cisneros
Borja G CosíoBorja G Cosío
Borja G Cosío
Chronic airflow obstruction affects a wide range of airway diseases, the most frequent of which are asthma, COPD, and bronchiectasis; they are clearly identifiable in their extremes, but quite frequently overlap in some of their pathophysiological and clinical characteristics. This has generated the description of new mixed or overlapping disease phenotypes with no clear biological grounds. In this special article, a group of experts provides their perspective and proposes approaching the treatment of chronic airway disease (CAD) through the identification of a series of therapeutic goals (TG) linked to treatable traits (TT) – understood as clinical, physiological, or biological characteristics that are quantifiable using biomarkers. This therapeutic approach needs validating in a clinical trial with the strategy of identification of TG and treatment according to TT for each patient independently of their prior diagnosis.

10 December 2013 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
GSGrupo Emergente de Asma (Gea) del Área de Asma de la Separ
Grupo Emergente de Asma (Gea) del Área de Asma de la Separ
JSJose Gregorio Soto-Campos
Jose Gregorio Soto-Campos
VPVicente Plaza
Vicente Plaza
JSJoan B Soriano
Joan B Soriano
CCCarlos Cabrera-Lopez
Carlos Cabrera-Lopez
VSVanessa Santos-Sánchez
Vanessa Santos-Sánchez
There is limited information on the causes of death in asthma patients.

11 November 2021 in Journal of Investigational Allergology and Clinical Immunology
Verified
Journal Article
Closed access
JIJl Izquierdo
Jl Izquierdo
CACarlos Almonacid
Carlos Almonacid
CCC Campos
C Campos
DMD Morena
D Morena
MBM Benavent
M Benavent
JRJm Rodríguez
Jm Rodríguez
Objective: The objective of the present study was to determine the use of systemic corticosteroids (SCs) in patients with bronchial asthma using big data analysis. Methods: We performed an observational, retrospective, noninterventional study based on secondary data captured from free text in the electronic health records. This study was performed based on data from the regional health service of Castille-La Mancha (SESCAM), Spain. We performed the analysis using big data and artificial intelligence via Savana (R) Manager version 3.0. Results: During the study period, 103 667 patients were diagnosed with and treated for asthma at different care levels. The search was restricted to patients aged 10 to 90 years (mean age, 43.5 [95%CI, 43.4-43.7] years). Of these, 59.8% were women. SCs were taken for treatment of asthma by 58 745 patients at some point during the study period. These patients were older, with a higher prevalence of hypertension, dyslipidemia, diabetes, obesity, depression, and hiatus hernia. SCs are used frequently in the general population with asthma (31.4% in 2015 and 39.6% in 2019). SCs were prescribed mainly in primary care (59%), allergy (13%), and pulmonology (20%). The frequency of prescription of SCs had a direct impact on the main associated adverse effects. Conclusion: In clinical practice, SCs are frequently prescribed to patients with asthma, especially in primary care. Use of SCs is associated with a greater number of adverse events. It is necessary to implement measures to reduce prescription of SCs to patients with asthma, especially in primary care.

4 January 2023 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
CACarlos Almonacid
Carlos Almonacid
EFEunice Fitas
Eunice Fitas
JSJoaquín Sánchez-Covisa
Joaquín Sánchez-Covisa
HGHéctor Gutiérrez
Héctor Gutiérrez
PRPablo Rebollo
Pablo Rebollo
Background: Although there are currently alternative treatments to the long-term use of oral corticosteroids (OCS) in severe asthma, recent studies show excessive use depending on geography and differences in medical practice. The objective of the study was to describe the differences in OCS use for severe asthma across the Spanish geography. Methods: This is a real-world study using existing databases (year 2019): longitudinal patient database (EMR), based on electronic medical records, and database of pharmacological consumption (Sell-in) in basic healthcare areas. With EMR, the percentage of OCS prescriptions corresponding to patients with severe asthma (ICD-9 “asthma” and prescription of biological treatment and/or high dose of inhaled corticosteroids/long-acting inhaled β2 agonists) was calculated. This percentage was transferred to the OCS consumption of each basic healthcare area as reported in the Sell-in database and a national heat map was created. The estimation of OCS use in patients with severe asthma per 100,000 inhabitants for each region was calculated by grouping basic healthcare areas and the mean OCS use per patient for different regions in Spain was also estimated. Results: Patients with severe asthma in Spain were mostly female (69.6%), with a mean age (SD) of 57.6 years (18.01). Median time (Pc25–Pc75) since asthma diagnosis was 83.1 months (34.65–131.56). Of all patients with OCS prescriptions in 2019 identified in EMR, 4.4% corresponded to patients with severe asthma. Regions with the highest OCS use were Asturias, Andalucía, and Galicia, whereas those with the lowest use were Navarra, Baleares, Madrid and País Vasco. The mean OCS use per patient with severe asthma in 2019 throughout Spain was 1099.85 mg per patient, ranging from 782.99 mg in Navarra to 1432.64 in Asturias. Conclusions: There are geographical differences between Spanish regions with respect to the use of OCS in patients with severe asthma. The national mean consumption of OCS per patient with severe asthma and year is above the limits that indicate good asthma control.

1 July 2025 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
CACarlos Almonacid
Carlos Almonacid
RGRaquel Gómez
Raquel Gómez
IMIgnacio Morán
Ignacio Morán
IMIrantzu Muerza
Irantzu Muerza
MPMariano Pastor
Mariano Pastor
DQDolors Querol
Dolors Querol
Purpose: Chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and asthma, pose a significant health risk due to the increasingly pronounced rise in its prevalence, associated complications and impact on patients’ quality of life. The aim of this study is to analyse the needs of patients with COPD and asthma throughout their patient journey. Patients and Methods: To this end, a qualitative and cross-sectional study was conducted based on interviews and focus groups. 28 people took part, including patients, relatives and representatives of patient associations, and they were selected to ensure a diversity of perspectives. The data collected were analyzed by two psychologists with experience in qualitative research, who conducted thematic analysis and made use of data saturation criteria. Results: The results emphasize that patient needs vary according to the stage of the disease. In the initial stage, patients find it difficult to identify symptoms and risk factors, and demand education on basic concepts and self-care strategies. When diagnosed, they require psycho-emotional support and training on the disease. Insufficient information, particularly concerning the use of inhalers and the different therapies, is a recurrent obstacle in treatment and monitoring. Furthermore, therapeutic nonadherence is affected by factors such as perception of the severity of the disease, related to the treatment and deficiencies in inhaler technique. Additionally, pulmonary rehabilitation and multidisciplinary care are unmet needs that have an impact on patients’ quality of life. Conclusion: The study highlights the importance of personalizing interventions according to the stage of the patient journey, combining education, disease coping strategies and comprehensive monitoring. Patient groups play a key role as they are a source of emotional support, guidance and self-care. In conclusion, a proposal is made for a patient-centred approach that promotes self-management, equitable access to resources and coordination between healthcare teams to optimise integrated care in respiratory diseases. In this respect, it seems relevant and appropriate to develop training environments for patients diagnosed with asthma/COPD and their carers, where information and training are offered to support good disease management in the different stages of the patient journey.

9 February 2021 in JMIR Formative Research
Verified
Journal Article
Open access
CACarlos Almonacid
Carlos Almonacid
CMCarlos Melero
Carlos Melero
AVAntolín López Viña
Antolín López Viña
CCCarolina Cisneros
Carolina Cisneros
LLLuis Pérez Pérez de Llano
Luis Pérez Pérez de Llano
AMAlfonso Muriel
Alfonso Muriel
Background: Poor adherence to inhaled medication in asthma patients is of great concern. It is one of the main reasons for inadequate asthma control. Objective: The goal of the research was to determine if motivational messages using short message service (SMS, or text) improved adherence to inhaled medication in patients with asthma. Methods: A prospective multicenter randomized parallel-group clinical trial was conducted in 10 asthma clinics in Spain. Adherence was assessed with electronic monitors (Smartinhaler, Adherium Ltd) connected to inhalers. Patients in the SMS group received psychologist-developed motivational messages every 3 days for 6 months. Results: There were 53 patients in the SMS group and 88 patients in the control group. After 6 months, mean electronic adherence was 70% (SD 17%) in the intervention group and 69% (SD 17%) in the control group (P=.82). Significant differences between the study groups in morning and evening adherence to inhaled therapy, asthma control, exhaled nitric oxide levels, or improvement of lung functions were not observed. Conclusions: Motivational messages were not useful to improve adherence to inhaled asthma medication compared with usual care.